Literature DB >> 19357858

[Vasculopathy in Sjögren's syndrome].

E Feist1, K-G A Hermann, A Dankof.   

Abstract

Sjögren's syndrome is a systemic autoimmune disease with a predominant involvement of exocrine glands leading to sicca symptoms. Extraglandular involvement occurs in about 40% of patients with skin, musculoskeletal, neurological and organ manifestations. Systemic vasculitic manifestations of Sjögren's syndrome can be assumed in approximately 5%-10% of patients. Leukocytoclastic or cryoglobulinemic vasculitis represent classic vasculitic manifestations of Sjögren's syndrome. In the pathogenesis of vasculitis, B-cell-driven autoimmune processes play a major role by producing autoantibodies against the Ro/SS-A and La/SS-B antigens and cryoglobulins. In patients with Sjögren's syndrome, manifestation of vasculitis, non-Hodgkin's lymphoma and glomerulonephritis, as well as positive cryoglobulins and decreased levels of complement factors, are considered negative prognostic markers. Various immunosuppressive strategies, usually in co-medication with glucocorticoids, are used for the treatment of vasculitis in Sjögren's syndrome. For refractory and severe manifestations, a B-cell-targeted therapy with Rituximab should be also considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357858     DOI: 10.1007/s00393-008-0400-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  42 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity.

Authors:  E L Alexander; F C Arnett; T T Provost; M B Stevens
Journal:  Ann Intern Med       Date:  1983-02       Impact factor: 25.391

3.  [Labial salivary gland biopsy in Sjögren's syndrome].

Authors:  A Dankof; L Morawietz; E Feist
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

4.  Expression of selectins (CD62 E,L,P) and cellular adhesion molecules in primary Sjögren's syndrome: questions to immunoregulation.

Authors:  K E Aziz; P J McCluskey; D Wakefield
Journal:  Clin Immunol Immunopathol       Date:  1996-07

5.  The spectrum of neurological involvement in Sjögren's syndrome.

Authors:  A P Andonopoulos; G Lagos; A A Drosos; H M Moutsopoulos
Journal:  Br J Rheumatol       Date:  1990-02

6.  Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients.

Authors:  Mario García-Carrasco; Antoni Sisó; Manuel Ramos-Casals; José Rosas; Gloria de la Red; Victor Gil; Susana Lasterra; Ricard Cervera; Josep Font; Miguel Ingelmo
Journal:  J Rheumatol       Date:  2002-04       Impact factor: 4.666

Review 7.  Acute self-limiting jejunitis as the first manifestation of microscopic polyangiitis associated with Sjogren's disease: report of one case and review of the literature.

Authors:  F Radaelli; G Meucci; G Spinzi; V Terruzzi; G Imperiali; N Lenoci; E Strocchi; A Sangiovanni; N Terreni; M Quarenghi; G Minoli
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-08       Impact factor: 2.566

8.  Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients.

Authors:  Sophie Delalande; Jérôme de Seze; Anne-Laure Fauchais; Eric Hachulla; Tanya Stojkovic; Didier Ferriby; Sylvain Dubucquoi; Jean-Pierre Pruvo; Patrick Vermersch; Pierre-Yves Hatron
Journal:  Medicine (Baltimore)       Date:  2004-09       Impact factor: 1.889

9.  Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.

Authors:  M Voulgarelis; S Giannouli; D Anagnostou; A G Tzioufas
Journal:  Rheumatology (Oxford)       Date:  2004-06-08       Impact factor: 7.580

10.  Sjögren syndrome: central nervous system manifestations.

Authors:  G E Alexander; T T Provost; M B Stevens; E L Alexander
Journal:  Neurology       Date:  1981-11       Impact factor: 9.910

View more
  4 in total

1.  Association between a History of herpes zoster and the risk of Sjögren's syndrome: a nationwide, population-based, case-control study.

Authors:  Pei Ju Huang; Shih-Ping Lin; Chun-Yi Wu; Yen-Tze Liu; Hsin-Hua Chen
Journal:  BMJ Open       Date:  2022-10-14       Impact factor: 3.006

Review 2.  [Critical overview of outcome parameters for patients with primary Sjögren's syndrome].

Authors:  E Feist; A Hansen
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

3.  Spontaneous intracranial hemorrhage as an initial manifestation of primary Sjögren's syndrome: a case report.

Authors:  Guo-Qiang Wang; Wei-Wei Zhang
Journal:  BMC Neurol       Date:  2013-07-29       Impact factor: 2.474

4.  Acute transverse myelitis and psoriasiform dermatitis associated with Sjoegren's syndrome: a case report.

Authors:  Carolin Kurz; Silke Wunderlich; Derek Spieler; Benedikt J Schwaiger; Christian Andres; Claudia Traidl-Hoffmann; Rüdiger Ilg
Journal:  BMC Res Notes       Date:  2014-08-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.